New drugs for rheumatoid arthritis: The industry point of view Stephen H. Polmar

Cardiovascular risk in rheumatoid arthritis. Up to what point? Víctor Martínez Taboada, Loreto Carmona

Rheumatoid Arthritis, a New Focus on Cardiovascular Risk Erardo Meriño-Ibarra, Concepción Delgado-Beltrán